Vyndaqel (tafamidis)

pCPA File Number: 21191

Negotiation Status:

Active Negotiation

Indication(s):

transthyretin-mediated amyloidosis

Sponsor/Manufacturer:

Pfizer Canada ULC

CADTH Project Number:

SR0625-000

pCPA Engagement Letter Issued:

2020-06-10

Negotiation Process Concluded:

Not Applicable